160 related articles for article (PubMed ID: 25605848)
21. Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer.
Piver RN; Wagner VM; Levine MD; Backes FJ; Chambers LJ; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Bixel KL
Gynecol Oncol Rep; 2023 Apr; 46():101156. PubMed ID: 36910448
[TBL] [Abstract][Full Text] [Related]
22. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
Nguyen CT; Stephenson AJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):593-604, ix. PubMed ID: 21570611
[TBL] [Abstract][Full Text] [Related]
23. Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.
Bamias A; Tzannis K; Dimitriadis I; Tsironis G; Papatheorodidi AM; Tsiara A; Fragkoulis C; Xirokosta A; Barbarousi D; Papadopoulos G; Zakopoulou R; Varkarakis I; Mitsogiannis I; Adamakis I; Alamanis C; Stravodimos K; Papatsoris AG; Dellis AE; Drivalos A; Ntoumas K; Matsouka H; Halvatsiotis P; Raptis A; Gerotziafas GT; Dimopoulos MA
Clin Genitourin Cancer; 2020 Aug; 18(4):e457-e472. PubMed ID: 32007440
[TBL] [Abstract][Full Text] [Related]
24. Treatment results in children and adolescents with loco-regional recurrences of abdominal germ cell tumors (GCTs): a pilot-study with PEI chemotherapy and regional deep hyperthermia (RHT) in comparison to a matched cohort.
Wessalowski R; Blohm M; Calaminus G; Engert J; Harms D; Krause I; Kruck H; Grüttner HP; Pape H; Göbel U
Klin Padiatr; 1997; 209(4):250-6. PubMed ID: 9293458
[TBL] [Abstract][Full Text] [Related]
25. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
[TBL] [Abstract][Full Text] [Related]
26. Khorana Score: Νew Predictor of Early Mortality in Patients With Lung Adenocarcinoma.
Vathiotis I; Dimakakos EP; Boura P; Ntineri A; Charpidou A; Gerotziafas G; Syrigos K
Clin Appl Thromb Hemost; 2018 Nov; 24(8):1347-1351. PubMed ID: 29806470
[TBL] [Abstract][Full Text] [Related]
27. Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery.
Rollins KE; Peters CJ; Safranek PM; Ford H; Baglin TP; Hardwick RH
Eur J Surg Oncol; 2011 Dec; 37(12):1072-7. PubMed ID: 21925829
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
29. Influence of type 2 diabetes mellitus on Khorana venous thromboembolism risk in colorectal cancer patients.
Wang R; Liu R; Zhao L; Xu D; Hu L
Rev Esp Enferm Dig; 2017 Jul; 109(7):503-509. PubMed ID: 28593781
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients.
Rupa-Matysek J; Lembicz M; Rogowska EK; Gil L; Komarnicki M; Batura-Gabryel H
Med Oncol; 2018 Apr; 35(5):63. PubMed ID: 29616356
[TBL] [Abstract][Full Text] [Related]
32. Impact of surgery, chemotherapy and irradiation on long term outcome of intracranial malignant non-germinomatous germ cell tumors: results of the German Cooperative Trial MAKEI 89.
Calaminus G; Bamberg M; Jürgens H; Kortmann RD; Sörensen N; Wiestler OD; Göbel U
Klin Padiatr; 2004; 216(3):141-9. PubMed ID: 15175958
[TBL] [Abstract][Full Text] [Related]
33. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
34. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
Lorch A; Bascoul-Mollevi C; Kramar A; Einhorn L; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin K; Lotz JP; Germà-Lluch JR; Powles T; Kollmannsberger C; Beyer J
J Clin Oncol; 2011 Jun; 29(16):2178-84. PubMed ID: 21444870
[TBL] [Abstract][Full Text] [Related]
35. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients.
Woller SC; Stevens SM; Jones JP; Lloyd JF; Evans RS; Aston VT; Elliott CG
Am J Med; 2011 Oct; 124(10):947-954.e2. PubMed ID: 21962315
[TBL] [Abstract][Full Text] [Related]
36. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients.
Thaler J; Preusser M; Ay C; Kaider A; Marosi C; Zielinski C; Pabinger I; Hainfellner JA
Thromb Res; 2013 Feb; 131(2):162-5. PubMed ID: 23084660
[TBL] [Abstract][Full Text] [Related]
37. Red cell distribution width and risk for venous thromboembolism: a population-based cohort study.
Zöller B; Melander O; Svensson P; Engström G
Thromb Res; 2014 Mar; 133(3):334-9. PubMed ID: 24393657
[TBL] [Abstract][Full Text] [Related]
38. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
39. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.
Khorana AA; Francis CW; Culakova E; Lyman GH
Cancer; 2005 Dec; 104(12):2822-9. PubMed ID: 16284987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
